Yaupon Therapeutics Inc. Secures $14.4 Million in Series D Financing
Published: Aug 11, 2011
Yaupon recently submitted a New Drug Application (NDA) to the FDA for a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, the most common type of cutaneous T-cell lymphoma (CTCL).
“This financing provides us with the necessary capital to take us through the NDA regulatory review process, while preparing for commercialization either alone or with an industry partner,” said Yaupon Chairman and CEO Steve Tullman. “We appreciate the strong support of existing and new investors and their ongoing confidence in the potential of our product for the treatment of this common type of CTCL.”
About Yaupon Therapeutics
Yaupon Therapeutics, a privately held, specialty pharmaceutical company, is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of cutaneous T-cell lymphoma (CTCL). If approved, Yaupon’s investigational drug would be the first topical mechlorethamine gel widely available to treat the signs and symptoms of this rare cancer. Please visit the new Yaupon website www.yaupontherapeutics.com for more information.
Yaupon Therapeutics, Inc.Media Contact:Sam Brown Inc.Mike Beyer, email@example.com